Previous reports on antimalarial toxicity have only been related to long-term continuous treatments for nonmalarial indications, which require prolonged use of large doses, up to 1000 g or more every year. We describe a patient with recurrent malaria, prophylactically treated with low-dose chloroquine, who developed heart failure due to biventricular cardiac dysfunction. The right ventricle endomyocardial biopsy was suggestive of chloroquine toxicity. The heart failure improved after drug withdrawal. As a consequence, the potential for reversibility and the severity in undiagnosed cases of these toxic cardiomyopathies emphasize the importance of recognizing early signs of toxicity in order to withdraw antimalarials before the occurrence of life-threatening cardiac toxicity.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00380-008-1144-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Protective mechanism of safflower yellow injection on myocardial ischemia-reperfusion injury in rats by activating NLRP3 inflammasome.
BMC Complement Med Ther
January 2025
Institute of Basic Medical Sciences of Xiyuan Hospital, Beijing Key Laboratory of Chinese Materia Pharmacology, China Academy of Chinese Medical Sciences, National Clinical Research Center of Traditional Chinese Medicine for Cardiovascular Diseases, Beijing, China.
Objectives: This study intended to explore whether the protective effect safflower yellow injection (SYI) on myocardial ischemia-reperfusion (I/R) injury in rats mediated of the NLRP3 inflammasome signaling.
Methods: The I/R model was prepared by ligating the left anterior descending coronary artery for 45 min and then releasing the blood flow for 150 min. 96 male Wistar rats were randomly divided into sham group, I/R group, Hebeishuang group (HBS), SYI high-dose group (I/R + SYI-H), SYI medium-dose group (I/R + SYI-M) and SYI low-dose group (I/R + SYI-L).
Efficacy of combining aspirin with hydroxychloroquine in pregnancies at high risk for pre-eclampsia: a prospective, multicentre, open-label, single-arm clinical trial, investigator-initiated study (HUGS study).
BMJ Open
December 2024
Department of Obstetrics and Gynecology, Samsung Medical Center, Seoul, Korea (the Republic of).
Introduction: The use of hydroxychloroquine (HCQ) during pregnancies complicated by systemic lupus erythematosus or refractory antiphospholipid antibody syndrome has demonstrated a significant ability to prevent pre-eclampsia (PE). As such, the potential for the administration of HCQ to prevent PE in other high-risk pregnancies is an important clinical research agenda among maternal and fetal medicine specialists. Mechanistically, the anti-inflammatory and immunomodulatory effects of HCQ can offer vascular protection and inhibit the placental dysfunction-associated thrombotic changes underlying the pathophysiology of PE, fetal growth restriction (FGR) and fetal death in utero (FDIU).
View Article and Find Full Text PDFPorphyria cutanea tarda: a unique iron-related disorder.
Hematology Am Soc Hematol Educ Program
December 2024
Harvard Medical School, Boston, MA.
The porphyrias are a group of disorders of heme biosynthesis, each characterized by an enzymatic defect in the heme biosynthetic pathway. Porphyria cutanea tarda (PCT) arises due to the inhibition of uroporphyrinogen decarboxylase (UROD) in the presence of hepatic iron and oxidative stress. Most patients with PCT have evidence of siderosis on liver biopsy, and the disease resolves with iron depletion.
View Article and Find Full Text PDFAnalysis of Pregnancy Outcomes in Patients Exhibiting Recurrent Miscarriage With Concurrent Low-Titer Antiphospholipid Antibodies.
Am J Reprod Immunol
November 2024
Department of Rheumatology and Immunology, The Third Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
Article Synopsis
- Antiphospholipid syndrome (APS) is an autoimmune disorder affecting blood clotting and pregnancy outcomes, defined by the presence of antiphospholipid antibodies (aPLs), with recent criteria requiring higher antibody levels for diagnosis.
- This study analyzed the pregnancy outcomes in 252 pregnancies of recurrent miscarriage (RM) patients, focusing on the effects of treatment in those with low-titer aPLs, splitting them into treated and untreated groups.
- Results showed varied positivity rates for different aPL types among treated and untreated patients, suggesting treatment may influence pregnancy success in women with low-titer aPLs, although outcomes were still being assessed.
How to treat patients with thrombotic antiphospholipid syndrome in 2024?
Pol Arch Intern Med
November 2024
Antiphospholipid syndrome (APS) encompasses a range of clinical conditions, particularly thrombotic or obstetrical manifestations, associated with the presence of antiphospholipid antibodies. Managing thrombotic APS in daily clinical practice can be challenging and requires thorough risk stratification and tailored treatment strategies. Primary prophylaxis focuses on correcting the traditional thrombotic risk factors and, in certain situations, may include low‑dose aspirin and / or prophylactic anticoagulants (eg, low‑molecular‑weight heparin).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!